| Identification | Back Directory | [Name]
VALNEMULIN | [CAS]
101312-92-9 | [Synonyms]
VALNEMULIN
2-[[2-[[(2R)-2-Amino-3-methyl-1-oxobutyl]amino]-1,1-dimethylethyl]thio]acetic Acid (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-Ethenyldecahydro-5-hydroxy-4,6,9,10- tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl Ester | [EINECS(EC#)]
1312995-182-4 | [Molecular Formula]
C31H54N2O5S | [MDL Number]
MFCD08460261 | [MOL File]
101312-92-9.mol | [Molecular Weight]
566.84 |
| Chemical Properties | Back Directory | [Appearance]
White to Off-White Solid | [Melting point ]
140-143°C | [Boiling point ]
672.7±55.0 °C(Predicted) | [density ]
1.13±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMF: Soluble; DMSO: Soluble; Ethanol: Soluble; Methanol: Soluble | [form ]
A solid | [pka]
14.65±0.70(Predicted) |
| Hazard Information | Back Directory | [Chemical Properties]
White to Off-White Solid | [Uses]
Semisynthetic antibiotic; derivative of pleuromutilin. Antibacterial | [Uses]
Valnemulin is a semi-synthetic pleuromutilin prepared by sequential reaction of pleuromutilin tosylate with 2-amino-1,1-dimethylethylthiol, coupling the free amine with a protected valine and then deprotection to provide the final product. Valnemulin is a broad spectrum antibiotic used to control gastrointestinal infections in animals and shows no cross resistance to other antibiotic classes. Like all the pleuromutilins, valnemulin inhibits protein synthesis by binding to domain V of 23S RNA. | [Description]
Valnemulin is a broad-spectrum pleuromutilin antibiotic that binds to peptidyl transferase in the 50S ribosomal subunit. It has been used in veterinary medicine to treat swine diseases including, B. hyodysenteriae and M. hyopneumoniae. | [in vivo]
Valnemulin (100 mg/kg, i.g., single dose) exhibits lung protectiv effects in LPS-induced acute lung injury in BALB/c mice[2].
Valnemulin hydrochloride (10 mg/kg, p.o.; 10 days) has a control effect in experimental infection of calves with Mycoplasma bovis, and can effectively eliminate Mycobacterium bovis in the lungs [3]. | Animal Model: | Lipopolysaccharide induced acute lung injury in BALB/c mice[2]. | | Dosage: | 100 mg/kg | | Administration: | i.g., single dose | | Result: | Reduced levels of neutrophils, lymphocytes and macrophages, and expressions of TNF-α, IL-6, and IL-1β in bronchoalveolar lavage fluid (BALF).
Increased superoxidase dismutase (SOD) activity in BALF, decreased myeloperoxidase (MAO) activity in lung. |
| Animal Model: | Mycoplasma bovis infection treated male calves aged 10-35 days[3] | | Dosage: | 10 mg/kg | | Administration: | p.o., 10 days | | Result: | Resulted in a rapid diminution of clinical signs, restoration of appetite and reversal of weight loss.
Effectively reduced the isolation of Pasteurella multocida from the calves, lungs.
|
|
|
|